2015 American Society of Clinical Oncology (ASCO) Annual Meeting
Pfizer Media Resources
This media resource page is designed to provide background materials supporting Pfizer Oncology presentations at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting. Please visit the links below for resources on our multiple oncology programs being showcased at ASCO. Additional materials will become available as meeting embargoes lift.
- Pfizer Oncology Data Presentations at the 2015 ASCO Annual Meeting (PDF)
- Merck KGaA, Darmstadt, Germany, and Pfizer to Present Data at ASCO for Avelumab, an Investigational Anti-PD-L1 Antibody (Press Release)
- Pfizer Announces Palbociclib More Than Doubled Progression-Free Survival in Phase 3 Trial for Patients With HR+, HER2- Metastatic Breast Cancer Whose Disease Has Progressed Following Endocrine Therapy (Press Release)
Product Fact Sheets
- PF-05082566 (4-1BB agonist) Fact Sheet (PDF)
- BOSULIF® (bosutinib) 500 mg Tablets Fact Sheet (PDF)
- IBRANCE® (palbociclib) Fact Sheet (PDF)
- INLYTA® (axitinib) 1 mg and 5 mg Tablets Fact Sheet (PDF)
- SUTENT® (sunitinib malate) Capsules Fact Sheet (PDF)
- TORISEL® (temsirolimus) Injection Fact Sheet (PDF)
- XALKORI® (crizotinib) Capsules Fact Sheet (PDF)
Infographics
- The Art of ADC Design: The Pfizer Approach (PDF)
- Early Stage Development: The Key to Demonstrating Biosimilarity (PDF)
Disease Backgrounders
- Lung Cancer Fact Sheet (PDF)
